Cantargia
Develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | SEK50.0m | Post IPO Debt | |
| Total Funding | 000k | ||
| SEK | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | (15 %) | (73 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | (80 %) | (101 %) | (190 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (81 %) | (113 %) | (2432 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Cantargia AB is a biotechnology company focused on developing innovative antibody-based therapies targeting the IL1RAP (Interleukin-1 Receptor Accessory Protein) for the treatment of cancer and inflammatory diseases. The company operates in the biopharmaceutical market, primarily serving patients with unmet medical needs in oncology and immunology. Cantargia's business model revolves around the research, development, and commercialization of its proprietary antibody therapies. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products. Cantargia's flagship product, CAN04, is currently in clinical trials for non-small cell lung cancer and pancreatic cancer, demonstrating promising results in tumor growth inhibition and increased sensitivity to chemotherapy. The company leverages its strong scientific foundation and strategic collaborations to advance its pipeline and bring novel treatments to market.
Keywords: biotechnology, IL1RAP, antibody therapy, cancer, inflammation, oncology, immunology, CAN04, clinical trials, biopharmaceutical.